<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290106</url>
  </required_header>
  <id_info>
    <org_study_id>2014p-002117</org_study_id>
    <nct_id>NCT02290106</nct_id>
  </id_info>
  <brief_title>Effects of Pitavastatin on Insulin Sensitivity and Liver Fat</brief_title>
  <official_title>Effects of Pitavastatin on Insulin Sensitivity and Liver Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HMG co-A reductase inhibitors, commonly called statins, are an effective treatment for
      dyslipidemia and atherosclerotic heart disease with proven mortality benefit. While the
      lipid-lowering effects of statins are well-known, other metabolic effects, including effects
      on glucose tolerance and ectopic fat distribution, are less completely understood. Recent
      studies have shown that some statins may increase the risk of diabetes. Further, research has
      suggested that statins may have some benefit in nonalcoholic fatty liver disease (NAFLD), a
      condition associated with obesity that includes increased fat in the liver (steatosis) and,
      in some cases, inflammation and hepatocellular damage (steatohepatitis). Pitavastatin,
      approved by the United States Food and Drug Administration (FDA) in 2009, is the most recent
      statin to enter the market. Unlike most statins, pitavastatin is not primarily metabolized
      through cytochrome P450 (CYP450), and thus has reduced potential for interactions with other
      medications that are metabolized by CYP450. Previous studies have suggested that pitavastatin
      may be neutral to glucose homeostasis and may improve hepatic lipid. Neither of these effects
      has been proven definitively, however, and the current proposal aims to characterize in
      detail the effects of pitavastatin on glucose homeostasis, hepatic steatosis, and
      steatohepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2015</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin-stimulated Glucose Uptake</measure>
    <time_frame>6 months</time_frame>
    <description>insulin-stimulated glucose uptake measured by euglycemic hyperinsulinemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Fat</measure>
    <time_frame>6 months</time_frame>
    <description>liver fat content as measured by 1H-magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>6 months</time_frame>
    <description>alanine aminotransferase at the 6 month timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>6 months</time_frame>
    <description>aspartate aminotransferase at 6 month timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Insulin Sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>hepatic insulin sensitivity assessed by glucose infusion rate corrected for fluctuations in serum glucose (&quot;M&quot;) during low-dose insulin clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Insulin Sensitivity Check Index (QUICKI)</measure>
    <time_frame>6 months</time_frame>
    <description>quantitative insulin sensitivity check index (QUICKI) at 6 months. Measure = 1/((log(glucose in mg/dL) + log(insulin in uU/mL))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Obesity</condition>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pitavastatin 4mg daily by mouth for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical placebo 4mg by mouth daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin</intervention_name>
    <arm_group_label>Pitavastatin</arm_group_label>
    <other_name>Livalo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men age 40-65yo

          2. BMI ≥ 27kg/m2 and waist circumference ≥102cm, high probability risk factors for NAFLD

          3. At least one of the following indicating insulin resistance: Fasting glucose ≥100mg/dL
             and &lt;126mg/dL, HOMA-IR &gt;2.0, and/or 2 hour glucose ≥140mg/dL and &lt;200mg/dL following
             standard glucose tolerance test.

          4. 10-year cardiovascular disease risk ≥5% by American Heart Association(AHA)/American
             College of Cardiology (ACC) Pooled Cohort Equations CV Risk Calculator or LDL ≥
             100mg/dL

          5. No use of any statin within 1 year of study entry and not being actively considered
             for statin therapy by a treating provider.

        Exclusion Criteria:

          1. Diagnosis of diabetes or use of anti-diabetic medications.

          2. Use of erythromycin, rifampin, cyclosporin, colchicine, or gemfibrozil.

          3. Use of statin therapy within 1 year prior to study entry as above. Use of any other
             lipid-modifying therapy (including fish oil, fibrates, niacin, gemfibrozil) within 6
             months of study entry.

          4. Contraindication to statin therapy.

          5. Creatinine &gt; upper limit of normal or known renal disease

          6. AST or ALT &gt; 3 times the upper limit of normal

          7. hemoglobin &lt; 10g/dL

          8. Contraindication to undergoing a magnetic resonance scan.

          9. Atherosclerotic cardiovascular disease or low-density lipoprotein cholesterol (LDL-C)
             ≥ 190mg/dL.

         10. Triglyceride ≥500mg/dL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takara L Stanley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 8, 2014</study_first_submitted>
  <study_first_submitted_qc>November 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <results_first_submitted>March 22, 2019</results_first_submitted>
  <results_first_submitted_qc>June 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Takara Stanley</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>statin (HMG-CoA Reductase Inhibitor)</keyword>
  <keyword>fatty liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02290106/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pitavastatin</title>
          <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>(All randomized participants participated in baseline assessments.)</population>
      <group_list>
        <group group_id="B1">
          <title>Pitavastatin</title>
          <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="6.5"/>
                    <measurement group_id="B2" value="52.9" spread="7"/>
                    <measurement group_id="B3" value="52.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein cholesterol (LDL-C, mg/dL)</title>
          <population>Only participants with baseline and final data were used in the calculation of baseline timepoints.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116" spread="18"/>
                    <measurement group_id="B2" value="125" spread="22"/>
                    <measurement group_id="B3" value="120" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose (mg/dL)</title>
          <population>Only participants with baseline and final data were used in the calculation of baseline timepoints.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" spread="9"/>
                    <measurement group_id="B2" value="97" spread="9"/>
                    <measurement group_id="B3" value="97" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homeostasis model of insulin resistance (HOMA-IR)</title>
          <population>Only participants with baseline and final data were used in the calculation of baseline timepoints.</population>
          <units>HOMA-IR Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="1.9"/>
                    <measurement group_id="B2" value="1.6" spread="1.0"/>
                    <measurement group_id="B3" value="1.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver fat content (hepatic fat fraction, %)</title>
          <description>This is the percent liver fat content as measured by magnetic resonance spectroscopy technique</description>
          <population>Only participants with baseline and final data were used in the calculation of baseline timepoints. Five additional participants (1 pitavastatin &amp; 4 placebo) were unable to complete MRI due to inability to fit in the scanner or unanticipated claustrophobia, and 1 scan had unusable data due to technical error.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="11"/>
                    <measurement group_id="B2" value="14" spread="11"/>
                    <measurement group_id="B3" value="16" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin-stimulated Glucose Uptake</title>
        <description>insulin-stimulated glucose uptake measured by euglycemic hyperinsulinemic clamp</description>
        <time_frame>6 months</time_frame>
        <population>All patients with results for baseline and final. In addition to 3 participants who did not finish the study, 2 participants were unable to undergo clamp.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin-stimulated Glucose Uptake</title>
          <description>insulin-stimulated glucose uptake measured by euglycemic hyperinsulinemic clamp</description>
          <population>All patients with results for baseline and final. In addition to 3 participants who did not finish the study, 2 participants were unable to undergo clamp.</population>
          <units>mg/kg/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.1"/>
                    <measurement group_id="O2" value="5.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Liver Fat</title>
        <description>liver fat content as measured by 1H-magnetic resonance spectroscopy</description>
        <time_frame>6 months</time_frame>
        <population>All participants with baseline and final data were analyzed. In addition to patients who discontinued from the study, some patients were unable to have MRI scan due to inability to fit in the scanner or unanticipated claustrophobia.</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Fat</title>
          <description>liver fat content as measured by 1H-magnetic resonance spectroscopy</description>
          <population>All participants with baseline and final data were analyzed. In addition to patients who discontinued from the study, some patients were unable to have MRI scan due to inability to fit in the scanner or unanticipated claustrophobia.</population>
          <units>% liver fat (hepatic fat fraction)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="11"/>
                    <measurement group_id="O2" value="14" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT)</title>
        <description>alanine aminotransferase at the 6 month timepoint</description>
        <time_frame>6 months</time_frame>
        <population>all patients with available data at baseline and final</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <description>alanine aminotransferase at the 6 month timepoint</description>
          <population>all patients with available data at baseline and final</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="38"/>
                    <measurement group_id="O2" value="27" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST)</title>
        <description>aspartate aminotransferase at 6 month timepoint</description>
        <time_frame>6 months</time_frame>
        <population>all patients with available data at baseline and final</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <description>aspartate aminotransferase at 6 month timepoint</description>
          <population>all patients with available data at baseline and final</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="23"/>
                    <measurement group_id="O2" value="26" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Insulin Sensitivity</title>
        <description>hepatic insulin sensitivity assessed by glucose infusion rate corrected for fluctuations in serum glucose (&quot;M&quot;) during low-dose insulin clamp</description>
        <time_frame>6 months</time_frame>
        <population>all patients with available data at baseline and final (note, in addition to 3 patients who discontinued, some patients were unable to undergo clamp procedure)</population>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Insulin Sensitivity</title>
          <description>hepatic insulin sensitivity assessed by glucose infusion rate corrected for fluctuations in serum glucose (&quot;M&quot;) during low-dose insulin clamp</description>
          <population>all patients with available data at baseline and final (note, in addition to 3 patients who discontinued, some patients were unable to undergo clamp procedure)</population>
          <units>mg/kg/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c (HbA1c)</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <units>% (hemoglobin A1c)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="0.5"/>
                    <measurement group_id="O2" value="5.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
        <description>quantitative insulin sensitivity check index (QUICKI) at 6 months. Measure = 1/((log(glucose in mg/dL) + log(insulin in uU/mL))</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pitavastatin</title>
            <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
          </group>
        </group_list>
        <measure>
          <title>Quantitative Insulin Sensitivity Check Index (QUICKI)</title>
          <description>quantitative insulin sensitivity check index (QUICKI) at 6 months. Measure = 1/((log(glucose in mg/dL) + log(insulin in uU/mL))</description>
          <units>QUICKI index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.02"/>
                    <measurement group_id="O2" value="0.15" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months (during study period)</time_frame>
      <desc>Patients were asked at every study visit to recall any adverse events. (Patients were not contacted following study completion.)</desc>
      <group_list>
        <group group_id="E1">
          <title>Pitavastatin</title>
          <description>pitavastatin 4mg daily by mouth for 6 months
pitavastatin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identical placebo 4mg by mouth daily for 6 months
PLACEBO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatic Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acute appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Acute chest pain with overnight hospitalization; cardiac etiology ruled out with normal cardiac enzymes and other testing</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea or Loose Stools</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Any Gastrointestinal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any Musculoskeletal Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle Cramps</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Takara Stanley, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177249109</phone>
      <email>tstanley@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

